Article
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2007
Sunaga Noriaki, Tomizawa Yoshio, Yanagitani Noriko, Iijima Hironobu, Kaira Kyoichi, Shimizu Kimihiro, Tanaka Shigebumi, Suga Tatsuo, Hisada Takeshi, Ishizuka Tamotsu, Saito Ryusei, Dobashi Kunio, Mori Masatomo
Abstract excerpt
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR tyrosine kinase inhibitor. The objective of this study was to prospectively evaluate the efficacy of gefitinib in patients w...
Topics
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- DNA, Neoplasm
- Disease Progression
- Drug Administration Schedule
- ErbB Receptors
- Exons
- Female
- Follow-Up Studies